Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2011-05-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Glucagonotropic Effect of Amino Acids in Humans
NCT05954923
Direct Versus Indirect Effect of Amino Acids on Hepatokines
NCT06240039
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
NCT05264727
Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose
NCT01919788
Physiology of GIP(1-30)NH2 in Humans
NCT04792762
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral amino acid mixture
Oral administration of amino acid mixture in healthy volunteers
Oral amino acid mixture
Amino acid mixture 2,93 ml/kg
Intravenous amino acid administration
Intravenous infusion of amino acid mixture in healthy volunteers
Intravenous amino acid administration
Amino acid mixture 2,93 ml/kg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral amino acid mixture
Amino acid mixture 2,93 ml/kg
Intravenous amino acid administration
Amino acid mixture 2,93 ml/kg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Liver disease
* Kidney disease
* Thyroid disease
20 Years
30 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lund University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bo Ahren
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Ahrén, PhD
Role: PRINCIPAL_INVESTIGATOR
Lund University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Clinical Sciences Lund, Lund University
Lund, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.